Bertagna F, Bosio G, Caobelli F, Motta F, Biasiotto G, Giubbini R Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. Jpn J Radiol. 2010 Apr;28(3):199-204. doi: 10.1007/s11604-009-0408-2. Epub 2010 May 1.
Beyer T, Pichler B A decade of combined imaging: from a PET attached to a CT to a PET inside an MR. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S1-2. doi: 10.1007/s00259-008-1041-5.
Bisdas S, Nägele T, Schlemmer HP, Boss A, Claussen CD, Pichler B, Ernemann U Switching on the lights for real-time multimodality tumor neuroimaging: The integrated positron-emission tomography/MR imaging system. AJNR Am J Neuroradiol. 2010 Apr;31(4):610-4. doi: 10.3174/ajnr.A1900. Epub 2009 Nov 26. Review.
Bornstedt A, Burgmaier M, Hombach V, Marx N, Rasche V Dual stack black blood carotid artery CMR at 3T: application to wall thickness visualization. J Cardiovasc Magn Reson. 2009 Nov 10;11:45. doi: 10.1186/1532-429X-11-45.
Calcagno C, Mani V, Ramachandran S, Fayad ZA Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis. 2010 Jun;13(2):87-99. doi: 10.1007/s10456-010-9172-2. Epub 2010 Jun 6. Review.
Calcagno C, Vucic E, Mani V, Goldschlager G, Fayad ZA Reproducibility of black blood dynamic contrast-enhanced magnetic resonance imaging in aortic plaques of atherosclerotic rabbits. J Magn Reson Imaging. 2010 Jul;32(1):191-8. doi: 10.1002/jmri.22225.
Cao Y, Li D, Shen Z, Normolle D Sensitivity of quantitative metrics derived from DCE MRI and a pharmacokinetic model to image quality and acquisition parameters. Acad Radiol. 2010 Apr;17(4):468-78. doi: 10.1016/j.acra.2009.10.021.
Cheng HL Investigation and optimization of parameter accuracy in dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2008 Sep;28(3):736-43. doi: 10.1002/jmri.21489.
Chowdhury FU, Shah N, Scarsbrook AF, Bradley KM [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J. 2010 Mar;86(1013):174-82. doi: 10.1136/pgmj.2009.079087. Review.
Golshani-Hebroni SG, Bessman SP Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr. 1997 Aug;29(4):331-8. Review.
Graebe M, Pedersen SF, Borgwardt L, Højgaard L, Sillesen H, Kjaer A Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). Eur J Vasc Endovasc Surg. 2009 Jun;37(6):714-21. doi: 10.1016/j.ejvs.2008.11.018. Epub 2008 Dec 27.
Hatsukami TS, Yuan C MRI in the early identification and classification of high-risk atherosclerotic carotid plaques. Imaging Med. 2010 Feb 1;2(1):63-75.
Hays AG, Hirsch GA, Kelle S, Gerstenblith G, Weiss RG, Stuber M Noninvasive visualization of coronary artery endothelial function in healthy subjects and in patients with coronary artery disease. J Am Coll Cardiol. 2010 Nov 9;56(20):1657-65. doi: 10.1016/j.jacc.2010.06.036.
Herzog H, Pietrzyk U, Shah NJ, Ziemons K The current state, challenges and perspectives of MR-PET. Neuroimage. 2010 Feb 1;49(3):2072-82. doi: 10.1016/j.neuroimage.2009.10.036. Epub 2009 Oct 21.
Hicks RJ, Lau EW PET/MRI: a different spin from under the rim. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S10-4. doi: 10.1007/s00259-008-0966-z.
Hofmann M, Pichler B, Schölkopf B, Beyer T Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S93-104. doi: 10.1007/s00259-008-1007-7. Review.
Huang SC, Hoffman EJ, Phelps ME, Kuhl DE Quantitation in positron emission computed tomography: 2. Effects of inaccurate attenuation correction. J Comput Assist Tomogr. 1979 Dec;3(6):804-14.
Hyafil F, Cornily JC, Rudd JH, Machac J, Feldman LJ, Fayad ZA Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology. J Nucl Med. 2009 Jun;50(6):959-65. doi: 10.2967/jnumed.108.060749. Epub 2009 May 14.
Kershaw LE, Cheng HL Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model. Magn Reson Med. 2010 Dec;64(6):1772-80. doi: 10.1002/mrm.22573. Epub 2010 Aug 16.
Kerwin W Imaging of plaque cellular activity with contrast enhanced MRI. Stud Health Technol Inform. 2005;113:360-83.
Kerwin WS, Cai J, Yuan C Noise and motion correction in dynamic contrast-enhanced MRI for analysis of atherosclerotic lesions. Magn Reson Med. 2002 Jun;47(6):1211-7.
Kim D, Axel L Multislice, dual-imaging sequence for increasing the dynamic range of the contrast-enhanced blood signal and CNR of myocardial enhancement at 3T. J Magn Reson Imaging. 2006 Jan;23(1):81-6. Erratum in: J Magn Reson Imaging. 2007 Apr;25(4):878.
Luo RC, Yih CC, Su KL Multisensor fusion and integration: approaches, applications, and future research directions IEEE Sensors Journal. 2002;2(2):107-119.
Luypaert R, Sourbron S, Makkat S, de Mey J Error estimation for perfusion parameters obtained using the two-compartment exchange model in dynamic contrast-enhanced MRI: a simulation study. Phys Med Biol. 2010 Nov 7;55(21):6431-43. doi: 10.1088/0031-9155/55/21/006. Epub 2010 Oct 15.
Mawlawi O, Townsend DW Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S15-29. doi: 10.1007/s00259-008-1016-6. Review.
Menezes LJ, Kayani I, Ben-Haim S, Hutton B, Ell PJ, Groves AM What is the natural history of 18F-FDG uptake in arterial atheroma on PET/CT? Implications for imaging the vulnerable plaque. Atherosclerosis. 2010 Jul;211(1):136-40. doi: 10.1016/j.atherosclerosis.2010.01.012. Epub 2010 Jan 22.
Moreno PR, Purushothaman KR, Fuster V, O'Connor WN Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. Circulation. 2002 May 28;105(21):2504-11.
Nakamura K, Kimura K, Otani S, Asada S, Kameno Y [Arrhythmia and its treatment after open-heart surgery--with particular reference to the effects of potassium administration]. Kyobu Geka. 1972 Jan;25(1):1-10. Japanese.
Ng TS, Procissi D, Wu Y, Jacobs RE A robust coregistration method for in vivo studies using a first generation simultaneous PET/MR scanner. Med Phys. 2010 May;37(5):1995-2003.
Padhani AR, Husband JE Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. Clin Radiol. 2001 Aug;56(8):607-20. Review.
Padhani AR Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging. 2002 Oct;16(4):407-22. Review.
Parker GJM, Padhani AR Quantitative MRI of the brain. Chapter 10: John Wiley & Sons, Ltd; 2004.
Ramachandran S, Calcagno C, Fayad ZA Filtering and Phase-correlation based registration of Dynamic Contrast-Enhanced Magnetic Resonance Images. International Society for Magnetic Resonance in Medicine (ISMRM). Stockholm, Sweden; 2010.
Sheikine Y, Akram K FDG-PET imaging of atherosclerosis: Do we know what we see? Atherosclerosis. 2010 Aug;211(2):371-80. doi: 10.1016/j.atherosclerosis.2010.01.002. Epub 2010 Feb 1. Review.
Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. Atherosclerosis. 2009 Nov;207(1):139-43. doi: 10.1016/j.atherosclerosis.2009.04.023. Epub 2009 Apr 24.
Slomka PJ, Baum RP Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S44-55. doi: 10.1007/s00259-008-0941-8. Review.
Tofts PS, Berkowitz B, Schnall MD Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med. 1995 Apr;33(4):564-8.
Tofts PS Optimal detection of blood-brain barrier defects with Gd-DTPA MRI-the influences of delayed imaging and optimised repetition time. Magn Reson Imaging. 1996;14(4):373-80.
Turkheimer FE, Aston JA, Asselin MC, Hinz R Multi-resolution Bayesian regression in PET dynamic studies using wavelets. Neuroimage. 2006 Aug 1;32(1):111-21. Epub 2006 Apr 27.
Underhill HR, Hatsukami TS, Fayad ZA, Fuster V, Yuan C MRI of carotid atherosclerosis: clinical implications and future directions. Nat Rev Cardiol. 2010 Mar;7(3):165-73. doi: 10.1038/nrcardio.2009.246. Epub 2010 Jan 26. Review.
van Dijk RA, Virmani R, von der Thüsen JH, Schaapherder AF, Lindeman JH The natural history of aortic atherosclerosis: a systematic histopathological evaluation of the peri-renal region. Atherosclerosis. 2010 May;210(1):100-6. doi: 10.1016/j.atherosclerosis.2009.11.016. Epub 2009 Nov 26.
von Schulthess GK, Schlemmer HP A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S3-9. doi: 10.1007/s00259-008-0940-9.
Walker-Samuel S, Leach MO, Collins DJ Evaluation of response to treatment using DCE-MRI: the relationship between initial area under the gadolinium curve (IAUGC) and quantitative pharmacokinetic analysis. Phys Med Biol. 2006 Jul 21;51(14):3593-602. Epub 2006 Jul 6.
Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging. 2009 Mar;36 Suppl 1:S56-68. doi: 10.1007/s00259-009-1078-0. Review.
Yankeelov TE, Gore JC Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and Examples. Curr Med Imaging Rev. 2009 May 1;3(2):91-107.
Yankeelov TE, Luci JJ, DeBusk LM, Lin PC, Gore JC Incorporating the effects of transcytolemmal water exchange in a reference region model for DCE-MRI analysis: theory, simulations, and experimental results. Magn Reson Med. 2008 Feb;59(2):326-35. doi: 10.1002/mrm.21449.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.